Hakkı KAYA, İbrahim GÜL, Ali ZORLU, Hasan YÜCEL

The effect of levosimendan in a patients with postinfarction ventricular septal de- fect

Bu yazı, akut miyokard infarktüsü sonrası ventriküler septal defekt (VSD) gelişen birhastanınklinik seyrini içermektedir. Cerrahiyi bekleme sürecinde, hastaya kardiyak koruma amacıylalevosimendan infüzyonu başlandı. İnfüzyon esnasında hastanın hemodinamisi kötüleşti.Hemodinamideki bozulmanın, levosimendan tedavisine sekonder soldan sağa şant miktarınınartışına bağlı olabileceği düşünüldü.

İnfarktüs sonrası ventriküler septal defektli hastada Levosimendan ın etkisi

This paper reports the clinic course of a patient with postinfarction ventricular septal defect (VSD).At the period to surgery, the patient received levosimendan for cardio-protection. During thelevosimendan infusion, the hemodynamics of the patient worsened. The impairment ofhemodynamics and mortality of the patient might be responded to the increase of the amount ofleft to right shunt, which had possibly occurred due to levosimendan treatment.

PDF

___

1. Pohjola-Sintonen S, Muller JE, Stone PH. Ventricular septal and free wall rupture complicating acute myocardial infarction: Expe- rience in the Multicenter Investiga- tion of Limitation of Infarct Size. Am Heart J 1989; 117: 809-18.
2. Van de Werf F, Bax J, Betriu A. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the Man- agement of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29: 2909-45.
3. Menon V, Webb JG, Hillis LD. Outcome and profile of ventricular septal rupture with cardiogenic shock after myocardial infarction: A report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries in cardiogenic shocK? J Am Coll Cardiol 2000; 36: 1110-6.
4. Maltais S, Ibrahim R, Basmadjian AJ. Postinfarction ventricular septal defects: Towards a new treatment algorithm? Ann Thorac Surg 2009; 87: 687-92.
5. Landoni G, Mizzi A, Biondi- Zoccai G. Reducing mortality in cardiac surgery with levosi- mendan: A meta-analysis of ran- domized controlled trials. J Cardi- othorac Vasc Anesth 2010; 24: 51- 7.
6. Moore CA, Nygaard TW, Kaiser DL. Postinfarction ventricular septal rupture: the importance of loca- tion of infarction and right ventricular function in determining survival. Circulation 1986; 74: 45- 55.
7. Mebazaa A, Nieminen MS, Packer M. Levosimendan vs dobutamine for patients with acute decompen- sated heart failure: The SURVIVE Randomized Trial. JAMA 2007; 297: 1883-91.
8. Boucek MM, Chang R, Synhorst DP. Hemodynamic consequences of inotropic support with digoxin or amrinone in lambs with ventric- ular septal defect. Pediatr Res 1985; 19: 887-91.
9. Momoi N, Sato M, Sato K. Hemo- dynamic effects III inhibitor in pa- tients with a large ventricular left- to-right shunt. Jpn Circ J 2000; 64: 249-53.
10. Yilmaz MB, Yontar C, Erdem A. Comparative effects of levosi- mendan and dobutamine on right ventricular function in patients with biventricular heart failure. Heart Vessels 2009; 24: 16-21.
11. Lowe JE, Gall SA Jr. As originally published in 1989: Correlates of survival with postinfarction ventricular septal defect. Ann Thorac Surg 1997; 63: 1508-9.